Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q41724569

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Early MRD response as a progno ...... acute lymphoblastic leukemia.

@en

type

Item

label

Early MRD response as a progno ...... acute lymphoblastic leukemia.

@en

prefLabel

Early MRD response as a progno ...... acute lymphoblastic leukemia.

@en

P1476

Early MRD response as a progno ...... acute lymphoblastic leukemia.

@en

P2093

Bohumír Procházka

http://www.w3.org/2001/XMLSchema#string

Cyril Šálek

http://www.w3.org/2001/XMLSchema#string

Czech Leukemia Study Group - for Life

http://www.w3.org/2001/XMLSchema#string

Eva Froňková

http://www.w3.org/2001/XMLSchema#string

František Folber

http://www.w3.org/2001/XMLSchema#string

Iuri Marinov

http://www.w3.org/2001/XMLSchema#string

Jiří Mayer

http://www.w3.org/2001/XMLSchema#string

Michael Doubek

http://www.w3.org/2001/XMLSchema#string

Petr Cetkovský

http://www.w3.org/2001/XMLSchema#string

P2860

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia.

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

P304

276-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12587

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cyril Šálek

Iuri Marinov

P577

2015-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277025232

http://www.w3.org/2001/XMLSchema#string

P698

25997106

http://www.w3.org/2001/XMLSchema#string

P921

leukemia